The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Randomized Controlled Trials
Purpose. The purpose of this meta-analysis was to evaluate the efficacy and safety of dexamethasone intravitreal implant (DEX) for the treatment of diabetic macular edema (DME) with retinal vein occlusion secondary to macular edema (RVO-ME). Materials and Methods. Relevant databases were searched to...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2022/4007002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561855239815168 |
|---|---|
| author | Li Xiaodong Xie Xuejun |
| author_facet | Li Xiaodong Xie Xuejun |
| author_sort | Li Xiaodong |
| collection | DOAJ |
| description | Purpose. The purpose of this meta-analysis was to evaluate the efficacy and safety of dexamethasone intravitreal implant (DEX) for the treatment of diabetic macular edema (DME) with retinal vein occlusion secondary to macular edema (RVO-ME). Materials and Methods. Relevant databases were searched to include randomized controlled trials (RCTs) evaluating DEX for DME and RVO-ME. The search was conducted until March 2022. Meta-analysis was performed using Rev Man 5.4.1 software after screening the literature by inclusion and exclusion criteria, extracting information, and evaluating the methodological quality of the included studies. Results. The study showed that DEX treatment of RVO-ME was associated with an improvement in best corrected visual acuity (BCVA) (MD = −9.08, 95% CI: −10.89–7.27, P<0.00001) and central retinal thickness (CRT) (MD = 93.47, 95% CI: 28.55–159.39, P=0.005). DEX treatment of DME was significantly better than anti-VEGF treatment in terms of CRT reduction (MD = −72.35, 95% CI: −115.0–29.69, P=0.0009). The safety study showed that the risk of cataract from RVO-ME (OR = 5.06, 95% CI: 1.96 to 13.06, P=0.0008) and the incidence of high intraocular pressure (OR = 6.67, 95% CI: 3.46 to 12.86, P<0.00001) were significantly higher with DEX than with anti-VEGF therapy. The risk of cataract from DME (OR = 4.70, 95% CI: 2.10 to 10.54, P=0.00022) was significantly higher with DEX than with anti-VEGF therapy (OR = 4.70, 95% CI: 2.10 to 10.54, P=0.0002). The incidence of high IOP (OR = 13.77, 95% CI: 4.96 to 38.18, P<0.00001) was significantly higher with DEX than with anti-VEGF therapy. Conclusions. In patients with DME and RVO-ME, DEX was more efficacious but slightly less safe than anti-VEGF therapy. |
| format | Article |
| id | doaj-art-846f25fff41c41958a057f3bbce8f618 |
| institution | Kabale University |
| issn | 2090-0058 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-846f25fff41c41958a057f3bbce8f6182025-02-03T01:24:09ZengWileyJournal of Ophthalmology2090-00582022-01-01202210.1155/2022/4007002The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Randomized Controlled TrialsLi Xiaodong0Xie Xuejun1Chengdu University of Traditional Chinese MedicineDepartment of OphthalmologyPurpose. The purpose of this meta-analysis was to evaluate the efficacy and safety of dexamethasone intravitreal implant (DEX) for the treatment of diabetic macular edema (DME) with retinal vein occlusion secondary to macular edema (RVO-ME). Materials and Methods. Relevant databases were searched to include randomized controlled trials (RCTs) evaluating DEX for DME and RVO-ME. The search was conducted until March 2022. Meta-analysis was performed using Rev Man 5.4.1 software after screening the literature by inclusion and exclusion criteria, extracting information, and evaluating the methodological quality of the included studies. Results. The study showed that DEX treatment of RVO-ME was associated with an improvement in best corrected visual acuity (BCVA) (MD = −9.08, 95% CI: −10.89–7.27, P<0.00001) and central retinal thickness (CRT) (MD = 93.47, 95% CI: 28.55–159.39, P=0.005). DEX treatment of DME was significantly better than anti-VEGF treatment in terms of CRT reduction (MD = −72.35, 95% CI: −115.0–29.69, P=0.0009). The safety study showed that the risk of cataract from RVO-ME (OR = 5.06, 95% CI: 1.96 to 13.06, P=0.0008) and the incidence of high intraocular pressure (OR = 6.67, 95% CI: 3.46 to 12.86, P<0.00001) were significantly higher with DEX than with anti-VEGF therapy. The risk of cataract from DME (OR = 4.70, 95% CI: 2.10 to 10.54, P=0.00022) was significantly higher with DEX than with anti-VEGF therapy (OR = 4.70, 95% CI: 2.10 to 10.54, P=0.0002). The incidence of high IOP (OR = 13.77, 95% CI: 4.96 to 38.18, P<0.00001) was significantly higher with DEX than with anti-VEGF therapy. Conclusions. In patients with DME and RVO-ME, DEX was more efficacious but slightly less safe than anti-VEGF therapy.http://dx.doi.org/10.1155/2022/4007002 |
| spellingShingle | Li Xiaodong Xie Xuejun The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Randomized Controlled Trials Journal of Ophthalmology |
| title | The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Randomized Controlled Trials |
| title_full | The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Randomized Controlled Trials |
| title_fullStr | The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Randomized Controlled Trials |
| title_full_unstemmed | The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Randomized Controlled Trials |
| title_short | The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Randomized Controlled Trials |
| title_sort | efficacy and safety of dexamethasone intravitreal implant for diabetic macular edema and macular edema secondary to retinal vein occlusion a meta analysis of randomized controlled trials |
| url | http://dx.doi.org/10.1155/2022/4007002 |
| work_keys_str_mv | AT lixiaodong theefficacyandsafetyofdexamethasoneintravitrealimplantfordiabeticmacularedemaandmacularedemasecondarytoretinalveinocclusionametaanalysisofrandomizedcontrolledtrials AT xiexuejun theefficacyandsafetyofdexamethasoneintravitrealimplantfordiabeticmacularedemaandmacularedemasecondarytoretinalveinocclusionametaanalysisofrandomizedcontrolledtrials AT lixiaodong efficacyandsafetyofdexamethasoneintravitrealimplantfordiabeticmacularedemaandmacularedemasecondarytoretinalveinocclusionametaanalysisofrandomizedcontrolledtrials AT xiexuejun efficacyandsafetyofdexamethasoneintravitrealimplantfordiabeticmacularedemaandmacularedemasecondarytoretinalveinocclusionametaanalysisofrandomizedcontrolledtrials |